View Older Stories View More Recent Stories
-
Canaccord Genuity Downgrades Penumbra (PEN) to Hold
-
UBS Downgrades Penumbra (PEN) to Neutral
-
Jefferies Downgrades Penumbra (PEN) to Hold
-
Needham Downgrades Penumbra (PEN) to Hold
-
Nephron Downgrades Penumbra (PEN) to Hold
-
Baird Downgrades Penumbra (PEN) to Neutral
-
Leerink Partners Downgrades Penumbra (PEN) to Market Perform
-
Truist Securities Downgrades Penumbra (PEN) to Hold
-
Citi Downgrades Penumbra (PEN) to Neutral
-
BTIG Downgrades Penumbra (PEN) to Neutral
-
Wells Fargo Downgrades Penumbra (PEN) to Equal Weight
-
Morgan Stanley on Boston Scientific (BSX): 'Stock is looking too cheap and has clear catalysts'
-
William Blair Downgrades Penumbra (PEN) to Market Perform
-
Piper Sandler Downgrades Penumbra (PEN) to Neutral
-
Penumbra surges on news of $14.5 billion Boston Scientific buyout, BSX down
-
Penumbra reports preliminary Q4 2025 revenue of $383-385 million
-
Penumbra (PEN) PT Raised to $379 at Leerink Partners
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
JPMorgan Upgrades Penumbra (PEN) to Overweight
-
Penumbra (PEN) PT Raised to $388 at Needham
-
Needham Reiterates Buy Rating on Penumbra (PEN)
-
Penumbra (PEN) PT Raised to $312 at Truist Securities
-
Penumbra (PEN) PT Raised to $355 at Canaccord Genuity
-
Penumbra (PEN) PT Raised to $286 at Evercore ISI
-
Penumbra trial shows blood clot removal device improves pulmonary embolism outcomes
-
Penumbra trial shows thrombectomy device outperforms standard treatment
-
Needham Upgrades Penumbra (PEN) to Buy
-
Needham Reiterates Hold Rating on Penumbra (PEN)
-
Evercore ISI Starts Penumbra (PEN) at Outperform
-
Penumbra promotes Shruthi Narayan to company president
-
Penumbra (PEN) PT Raised to $335 at UBS
-
Penumbra (PEN) PT Lowered to $325 at RBC Capital
-
Penumbra (PEN) PT Raised to $350 at Canaccord Genuity
-
Penumbra, Inc. (PEN) Tops Q2 EPS by 3c, provides guidance
-
BTIG names top large-cap picks for second half of 2025
-
Penumbra stock surges on approval hopes
-
Penumbra (PEN) PT Raised to $330 at UBS
-
Penumbra (PEN) PT Raised to $318 at Stifel
-
Penumbra (PEN) PT Raised to $320 at BTIG
-
Penumbra, Inc. (PEN) Tops Q1 EPS by 16c, reiterates guidance
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
BofA Securities Starts Penumbra (PEN) at Buy
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Penumbra, Inc. (PEN) announces retirement of Don Kassing from Board
-
Penumbra (PEN) PT Raised to $320 at UBS
-
Penumbra (PEN) PT Raised to $340 at Canaccord Genuity
-
Penumbra (PEN) PT Raised to $308 at BTIG, Top Pick
-
Penumbra, Inc. (PEN) Tops Q4 EPS by 7c, provides guidance
-
MedTech sector outlook for 2025: Truist Securities
-
UBS Starts Penumbra (PEN) at Buy

